An online survey of tobacco smoking cessation associated with naturalistic psychedelic use - PubMed (original) (raw)
An online survey of tobacco smoking cessation associated with naturalistic psychedelic use
Matthew W Johnson et al. J Psychopharmacol. 2017 Jul.
Abstract
Data suggest psychedelics such as psilocybin and lysergic acid diethylamide (LSD) may hold therapeutic potential in the treatment of addictions, including tobacco dependence. This retrospective cross-sectional anonymous online survey characterized 358 individuals (52 females) who reported having quit or reduced smoking after ingesting a psychedelic in a non-laboratory setting ⩾1 year ago. On average, participants smoked 14 cigarettes/day for 8 years, and had five previous quit attempts before their psychedelic experience. Of the 358 participants, 38% reported continuous smoking cessation after psychedelic use (quitters). Among quitters, 74% reported >2 years' abstinence. Of the 358 participants, 28% reported a persisting reduction in smoking (reducers), from a mode of 300 cigarettes/month before, to a mode of 1 cigarette/month after the experience. Among reducers, 62% reported >2 years of reduced smoking. Finally, 34% of the 358 participants (relapsers) reported a temporary smoking reduction before returning to baseline smoking levels, with a mode time range to relapse of 3-6 months. Relapsers rated their psychedelic experience significantly lower in personal meaning and spiritual significance than both other groups. Participants across all groups reported less severe affective withdrawal symptoms (e.g. depression, craving) after psychedelic use compared with previous quit attempts, suggesting a potential mechanism of action for psychedelic-associated smoking cessation/reduction. Changes in life priorities/values were endorsed as the most important psychological factor associated with smoking cessation/reduction. Results suggest psychedelics may hold promise in treating tobacco addiction as potentially mediated by spiritual experience, changed priorities/values, and improved emotional regulation.
Keywords: Hallucinogen; addiction; mystical experience; nicotine; psilocybin; psychedelic; smoking cessation; tobacco.
Figures
Figure 1.
Distribution of participants reporting persisting smoking reduction (Reduce group) by duration of reduction is shown on the left. Distribution of participants reporting ongoing smoking abstinence (Quit group) by duration of abstinence is shown on the right.
Figure 2.
Group differences in smoking craving as assessed by the Questionnaire on Smoking Urges (QSU) from pre- to post-reference psychedelic experience. Retrospective ratings showed no significant differences among the groups. Current ratings showed significant difference among all three of the groups (p < 0.001).
Figure 3.
Relationship between Mystical Experience Questionnaire (MEQ30) and Tellegen Absorption Scale scores. Data points show data from each of the 358 individual participants with best-fit linear regression.
References
- Albaugh BJ and Anderson PO (1974). Peyote in the treatment of alcoholism among American Indians. American Journal of Psychiatry, 131(11), 1247–1250. -PubMed
- Bagby RM, Parker JD, and Taylor GJ (1994). The 20-item Toronto Alexithymia Scale: 1. Item selection and cross-validation of the factor structure. Journal of Psychosomatic Research, 38(1), 23–32. -PubMed
- Bergman RL (1971). Navajo peyote use: Its apparent safety. American Journal of Psychiatry, 128(6), 695–699. -PubMed
- Blum K, Futterman SFL, and Pascarosa P (1977). Peyote, a potential ethnopharmacologic agent for alcoholism and other drug dependencies: Possible biochemical rationale. Clinical Toxicology, 11(4), 459–472. -PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical